ArticleGenes & genomics2025
The PAR-score based on PANoptosis genes predicts the progression of ulcerative colitis and the response to anti-TNF-α treatment.
Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment of Inflammatory Bowel Disease with Drugs Targeting PANoptosis: A Comprehensive Review.Biomedicines · 2026Review
- A multi-machine learning framework identifies novel PANoptosis-related biomarkers and their immune landscape in ulcerative colitis: Insights from transcriptomics and experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUlcerative colitis (UC), a chronic inflammatory bowel disease, carries an elevated risk of colitis-associated colorectal cancer (CAC). While PANoptosis-a coordinated cell death mechanism integrating pyroptosis, apoptosis, and necroptosis-has been linked to inflammatory disorders, its role in UC progression and CAC transformation remains undefined.
objectiveTo delineate PANoptosis-related signatures and develop predictive models for the assessment of UC and CAC.
methodsTranscriptomic data from UC patients, CAC cases, and controls (GEO database) were analyzed to identify PANoptosis-associated genes. Enrichment and immune infiltration analyses elucidated functional roles, while a dextran sulfate sodium (DSS)-induced murine colitis model validated candidate gene expression via Western blot. Single-cell sequencing dissected cellular heterogeneity, Mendelian randomization established causality, and molecular docking screened therapeutic agents.
resultsFour PANoptosis hub genes (CASP1, LCN2, STAT3, ZBP1) were identified as UC drivers. The PANoptosis-Associated Risk Score (PAR-Score) demonstrated robust diagnostic accuracy (AUC > 0.75) and stratified disease activity, anti-TNF-α responsiveness, and CAC risk. Molecular docking revealed strong binding affinity between epidermal growth factor receptor (EGFR) inhibitors and target proteins (binding energy: -6.0 to -8.4 kcal/mol), suggesting therapeutic potential.
conclusionThe PAR-Score based on PANoptosis genes predicts the progression of UC and the response to anti-TNF-α treatment. EGFR inhibitors may serve as potential therapeutic agents for UC and CAC.
Indexed as
Identifiers
40932643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.